You are here: Industry Insights > wet AMD

News List

Clearside Biomedical Completes Dosing in First Cohort Trial of CLS-AX for Wet AMD americanpharmaceuticalreview
March 05, 2021
Clearside Biomedical announced completion of dosing in the first cohort of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).
NICE recommends Beovu (brolucizumab) for treatment of wet AMD europeanpharmaceuticalreview
February 07, 2021
NICE has issued final guidance recommending Beovu (brolucizumab) to treat wet age-related macular degeneration in adults.
EyePoint Announces First Patient Dosed in Trial of EYP-1901 for Wet AMD americanpharmaceuticalreview
February 03, 2021
EyePoint Pharmaceuticals announced that the first patient has been dosed in the Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD).
Clearside Biomedical Begins Enrollment for CLS-AX Trial for Wet AMD americanpharmaceuticalreview
January 20, 2021
Clearside Biomedical announced the first patients have been enrolled in its Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).
REGENXBIO Announces Dosing of First Patient in Trial for Wet AMD Using Suprachoroidal Delivery americanpharmaceuticalreview
September 14, 2020
REGENXBIO announced the first patient has been dosed in the AAVIATE trial, a Phase II trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of wet age-related macular degeneration (wet AMD).
Early trial shows application of RXi’s skin-scar drug in wet AMD fiercebiotech
August 02, 2018
RXi Pharmaceuticals unveiled positive safety and efficacy results in an early-phase study of its antifibrotic agent RXI-109 in patients with advanced neovascular age-related macular degeneration.......